drugset / Trial / NCT01453101
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
Timeline
- Start
- 2010-06-09
- Primary completion
- 2020-06-11
- Completion
- 2020-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |